Goldman Sachs’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.59M Buy
344,541
+36,601
+12% +$735K ﹤0.01% 3500
2026
Q2
$6.32M Sell
307,940
-3,483
-1% -$59K ﹤0.01% 3675
2026
Q1
$4.95M Sell
311,423
-37,110
-11% -$805K ﹤0.01% 3700
2025
Q4
$9.16M Buy
348,533
+164,535
+89% +$4.27M ﹤0.01% 3174
2025
Q3
$4.16M Buy
183,998
+67,464
+58% +$1.39M ﹤0.01% 3816
2025
Q2
$2.32M Sell
116,534
-86,286
-43% -$1.68M ﹤0.01% 4062
2025
Q1
$3.43M Buy
202,820
+45,279
+29% +$771K ﹤0.01% 3715
2024
Q4
$2.91M Buy
157,541
+29,818
+23% +$582K ﹤0.01% 3977
2024
Q3
$2.78M Buy
127,723
+28,746
+29% +$643K ﹤0.01% 3851
2024
Q2
$1.94M Buy
98,977
+15,207
+18% +$317K ﹤0.01% 3949
2024
Q1
$1.82M Sell
83,770
-18,642
-18% -$463K ﹤0.01% 3933
2023
Q4
$2.96M Sell
102,412
-1,290
-1% -$34.5K ﹤0.01% 3607
2023
Q3
$2.77M Sell
103,702
-28,113
-21% -$960K ﹤0.01% 3503
2023
Q2
$4.88M Buy
131,815
+60,820
+86% +$2.12M ﹤0.01% 3133
2023
Q1
$2.22M Buy
70,995
+20,530
+41% +$661K ﹤0.01% 3779
2022
Q4
$1.5M Sell
50,465
-25,097
-33% -$898K ﹤0.01% 4145
2022
Q3
$2.88M Buy
75,562
+34,157
+82% +$1.71M ﹤0.01% 3637
2022
Q2
$2.26M Sell
41,405
-76,132
-65% -$4.18M ﹤0.01% 3939
2022
Q1
$7.34M Buy
117,537
+83,678
+247% +$5.51M ﹤0.01% 2994
2021
Q4
$3.4M Sell
33,859
-400
-1% -$35.2K ﹤0.01% 3777
2021
Q3
$3.08M Buy
34,259
+11,663
+52% +$1.06M ﹤0.01% 3794
2021
Q2
$2.08M Buy
22,596
+5,441
+32% +$434K ﹤0.01% 4164
2021
Q1
$1.66M Buy
17,155
+5,074
+42% +$524K ﹤0.01% 4167
2020
Q4
$630K Buy
12,081
+1,927
+19% +$80.5K ﹤0.01% 4476
2020
Q3
$407K Buy
+10,154
New +$318K ﹤0.01% 4593
2020
Q2
– Sell
-31,131
Closed -$335K – 5293
2020
Q1
$335K Buy
+31,131
New +$434K ﹤0.01% 4438
2017
Q1
– Sell
-14,167
Closed -$164K – 6842
2016
Q4
$164K Sell
14,167
-6,833
-33% -$64.5K ﹤0.01% 5903
2016
Q3
$194K Buy
+21,000
New +$193K ﹤0.01% 5850

Other funds holding FLGT

Goldman Sachs's FLGT Position: Q3 2026 in Review

Goldman Sachs increased its Fulgent Genetics (FLGT) stake by 12% in Q3 2026, buying an estimated $735K and bringing the position to 344,541 shares worth $7.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3500.

Goldman Sachs first reported a position in FLGT in Q3 2016 and has held it in 28 quarters since. The position peaked at $9.16M in Q4 2025. 142 funds tracked by Wall St. Rank hold FLGT as of Q3 2026.

  • Goldman Sachs held 344,541 shares of Fulgent Genetics worth $7.59M as of Q3 2026.
  • Goldman Sachs bought 36,601 Fulgent Genetics shares in Q3 2026, an estimated $735K.
  • Fulgent Genetics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #3500 holding.
  • Goldman Sachs first reported a position in Fulgent Genetics in Q3 2016 and has held it in 28 quarters since.
  • Goldman Sachs's Fulgent Genetics position peaked at $9.16M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.